OUR STORY

 

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.
 
The 2020 edition will be in its 15th year and it continues to grow and attracts a large audience of biotech, pharma, payers, regulators, start-ups, investors, researchers and tech companies from around the world.
 
The conference and exhibition will host over 2000 attendees, 400 speakers and 100 exhibition booths. Over 500 different global companies are represented every year at this event. 

 

 

2000+
Attendees
500+
Companies
300+
Speakers
200+
Exhibitors
12
Conference Tracks
8
Workshops
80%
Decision Makers

 

NEW FOR 2020

 

Over the three days we will feature 300 presentations, 30 roundtable debates and several hours of networking. The first day will feature several important summits on everything from Rare Diseases, Investment, Development of Standards and Logistics.

The event is an experience designed to help you get the most out of the 2 or 3 days that you are in attendance.

The exhibition will feature two full days of content on our Pitch & Partner and Innovation Zone stages where exhibition visitors will be able to hear about some of the latest innovations from start-ups, labs and accelerators.

In short, this year promises to be the most spectacular event yet. 

 

 

NEW DATES

The event has moved to 30 March - 1 April 

Gene Therapy
Gene-edited therapeutics
Immunotherapy
Investment
Pitch & Partner

 

 
 

SIGN UP FOR EVENT UPDATES

Sign up now and get 15% off your ticket

Sign Up for Event Updates

 

WORLD CLASS CONFERENCE COVERING:

 
 
Cell therapy

Cell Therapy

Immunotherapy Immunotherapy

Pricing and Market Access Pricing and Market Access

Manufacturing Manufacturing & Bioprocess

Clinical Trials

Clinical Trials 

Rare Disease Rare Disease

Cord Blood Cord Blood

Gene Editing Gene Editing

Regenerative Medicine

Regenerative Medicine

Pitch & Partner Pitch & Partner

Logistics End to End Logistics

Gene Therapy Gene Therapy